Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 8900 results

  1. Sacituzumab tirumotecan for treating advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma after 2 or more treatment lines [TSID12301]

    Awaiting development Reference number: GID-TA11932 Expected publication date: TBC

  2. Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [TSID12305]

    Awaiting development Reference number: GID-TA11933 Expected publication date: TBC

  3. ID6611 Obesity, overweight - semaglutide (including review of TA875)

    Awaiting development Reference number: GID-TA11851 Expected publication date: TBC

  4. CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)

    In development Reference number: GID-HTE10085 Expected publication date: TBC

  5. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

  6. Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]

    Awaiting development Reference number: GID-TA11198 Expected publication date: TBC

  7. Intradiscal oxygen-ozone treatment of symptomatic lumbar disc herniation

    Topic prioritisation

  8. Insertion of Stoma Preservation Device

    Topic prioritisation

  9. Botulinum Toxin injection prior to Abdominal wall reconstruction

    Topic prioritisation

  10. AHEAD implants for external ear prosthesis

    Topic prioritisation

  11. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

  12. Osteoporosis

    In development Reference number: GID-QS10188 Expected publication date: TBC

  13. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development Reference number: GID-TA10994 Expected publication date: TBC

  14. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development Reference number: GID-TA10971 Expected publication date: TBC

  15. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC